FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

Dostarlimab becomes first FDA-approved immunotherapy for locally advanced rectal cancer
Patients now have an alternative to the brutal, life-altering standard of care

FDA has granted an accelerated approval to dostarlimab-gxly (Jemperli), making it the first and only immunotherapy approved in the U.S. for adults with locally advanced rectal cancers.

October 23, 2026

Vol.52 No.39

By Claire Marie Porter

In Brief

Jessica Zeller named director of the Office of Compliance and Enforcement, FDA Center for Tobacco Products

Jessica Zeller was named director of the Office of Compliance and Enforcement at the FDA Center for Tobacco Products.

October 23, 2026

Vol.52 No.39

In Brief

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Funding Opportunities

International Myeloma Society opens applications for over $3M in 2027 research funding

The International Myeloma Society, in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis, and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

An investigational CAR T therapy can lead to deep and durable responses in people with relapsed/refractory multiple myeloma, according to a phase I clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

Drugs & Targets

FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

FDA has granted a traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high [≥13 mutations/megabase] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

October 23, 2026

Vol.52 No.39

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

YOU MAY BE INTERESTED IN

Dostarlimab becomes first FDA-approved immunotherapy for locally advanced rectal cancer
Patients now have an alternative to the brutal, life-altering standard of care

Jessica Zeller named director of the Office of Compliance and Enforcement, FDA Center for Tobacco Products

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

YOU MAY BE INTERESTED IN

Dostarlimab becomes first FDA-approved immunotherapy for locally advanced rectal cancerPatients now have an alternative to the brutal, life-altering standard of care

Jessica Zeller named director of the Office of Compliance and Enforcement, FDA Center for Tobacco Products

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

Never miss an issue!

Login

Dostarlimab becomes first FDA-approved immunotherapy for locally advanced rectal cancer
Patients now have an alternative to the brutal, life-altering standard of care